JP2009503093A - インスリン産生細胞の機能を保持する方法 - Google Patents
インスリン産生細胞の機能を保持する方法 Download PDFInfo
- Publication number
- JP2009503093A JP2009503093A JP2008525132A JP2008525132A JP2009503093A JP 2009503093 A JP2009503093 A JP 2009503093A JP 2008525132 A JP2008525132 A JP 2008525132A JP 2008525132 A JP2008525132 A JP 2008525132A JP 2009503093 A JP2009503093 A JP 2009503093A
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- patient
- dose
- use according
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 813
- 108090001061 Insulin Proteins 0.000 title claims abstract description 407
- 229940125396 insulin Drugs 0.000 title claims abstract description 407
- 102000004877 Insulin Human genes 0.000 title claims abstract description 406
- 238000000034 method Methods 0.000 title abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 61
- 239000003814 drug Substances 0.000 claims abstract description 44
- 230000006362 insulin response pathway Effects 0.000 claims abstract description 39
- 235000005911 diet Nutrition 0.000 claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 229940079593 drug Drugs 0.000 claims abstract description 25
- 230000037213 diet Effects 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 230000001419 dependent effect Effects 0.000 claims abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 152
- 239000008103 glucose Substances 0.000 claims description 149
- 210000004369 blood Anatomy 0.000 claims description 82
- 239000008280 blood Substances 0.000 claims description 82
- 235000012054 meals Nutrition 0.000 claims description 67
- 206010012601 diabetes mellitus Diseases 0.000 claims description 60
- 210000002966 serum Anatomy 0.000 claims description 47
- 230000003914 insulin secretion Effects 0.000 claims description 36
- 230000006870 function Effects 0.000 claims description 33
- 210000000496 pancreas Anatomy 0.000 claims description 32
- 108010076181 Proinsulin Proteins 0.000 claims description 25
- 230000001965 increasing effect Effects 0.000 claims description 21
- 238000002560 therapeutic procedure Methods 0.000 claims description 20
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 18
- BBNKIRVUCQNAQR-FETIZUMASA-N (e)-4-[4-[(2s,5s)-5-[4-[[(e)-3-carboxyprop-2-enoyl]amino]butyl]-3,6-dioxopiperazin-2-yl]butylamino]-4-oxobut-2-enoic acid Chemical compound OC(=O)\C=C\C(=O)NCCCC[C@@H]1NC(=O)[C@H](CCCCNC(=O)\C=C\C(O)=O)NC1=O BBNKIRVUCQNAQR-FETIZUMASA-N 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- 230000000378 dietary effect Effects 0.000 claims description 11
- 230000035882 stress Effects 0.000 claims description 10
- 229940094417 fumaryl diketopiperazine Drugs 0.000 claims description 9
- 239000003018 immunosuppressive agent Substances 0.000 claims description 9
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 8
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 8
- 230000036542 oxidative stress Effects 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 230000000291 postprandial effect Effects 0.000 claims description 7
- 230000003915 cell function Effects 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims description 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 4
- 208000001280 Prediabetic State Diseases 0.000 claims description 3
- 108091005995 glycated hemoglobin Proteins 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000013268 sustained release Methods 0.000 claims description 3
- 239000012730 sustained-release form Substances 0.000 claims description 3
- 229940122199 Insulin secretagogue Drugs 0.000 claims description 2
- 229940122355 Insulin sensitizer Drugs 0.000 claims description 2
- 230000006472 autoimmune response Effects 0.000 claims description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 44
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 41
- 238000011282 treatment Methods 0.000 description 36
- 238000007920 subcutaneous administration Methods 0.000 description 25
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 18
- 208000013016 Hypoglycemia Diseases 0.000 description 17
- 206010022489 Insulin Resistance Diseases 0.000 description 16
- 230000002218 hypoglycaemic effect Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 238000002054 transplantation Methods 0.000 description 14
- 230000029142 excretion Effects 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 230000002685 pulmonary effect Effects 0.000 description 12
- 230000009471 action Effects 0.000 description 11
- 210000004153 islets of langerhan Anatomy 0.000 description 11
- 239000011859 microparticle Substances 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 235000011888 snacks Nutrition 0.000 description 11
- 230000005856 abnormality Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 238000012377 drug delivery Methods 0.000 description 7
- 201000001421 hyperglycemia Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 6
- 108010075254 C-Peptide Proteins 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000003278 mimic effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- -1 eighteen Chemical compound 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000001851 biosynthetic effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000014101 glucose homeostasis Effects 0.000 description 3
- 229940093181 glucose injection Drugs 0.000 description 3
- 230000010030 glucose lowering effect Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 230000000580 secretagogue effect Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- PXGPLTODNUVGFL-NAPLMKITSA-N 8-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-NAPLMKITSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003409 anti-rejection Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000009230 endogenous glucose production Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 210000002989 hepatic vein Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012737 microarray-based gene expression Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 2
- 229940127017 oral antidiabetic Drugs 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 238000013293 zucker diabetic fatty rat Methods 0.000 description 2
- NUYHTXOPSQBZKC-UHFFFAOYSA-N 3,6-bis(4-aminobutyl)piperazine-2,5-dione Chemical class NCCCCC1NC(=O)C(CCCCN)NC1=O NUYHTXOPSQBZKC-UHFFFAOYSA-N 0.000 description 1
- 108010065691 Biphasic Insulins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000034706 Graft dysfunction Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010026951 Short-Acting Insulin Proteins 0.000 description 1
- 229940123958 Short-acting insulin Drugs 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006470 autoimmune attack Effects 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 229960005347 belatacept Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000000189 biphasic insulin Substances 0.000 description 1
- 230000006406 biphasic response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000001517 counterregulatory effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940048956 glucagon injection Drugs 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 230000023187 negative regulation of glucagon secretion Effects 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- 229940112879 novolog Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000010503 organ complication Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000003820 β-cell dysfunction Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70429505P | 2005-08-01 | 2005-08-01 | |
| PCT/US2006/030014 WO2007016600A2 (en) | 2005-08-01 | 2006-08-01 | Method of preserving the function of insulin-producing cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015002059A Division JP2015091854A (ja) | 2005-08-01 | 2015-01-08 | インスリン産生細胞の機能を保持する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009503093A true JP2009503093A (ja) | 2009-01-29 |
| JP2009503093A5 JP2009503093A5 (enExample) | 2009-09-03 |
Family
ID=37561086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525132A Pending JP2009503093A (ja) | 2005-08-01 | 2006-08-01 | インスリン産生細胞の機能を保持する方法 |
| JP2015002059A Pending JP2015091854A (ja) | 2005-08-01 | 2015-01-08 | インスリン産生細胞の機能を保持する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015002059A Pending JP2015091854A (ja) | 2005-08-01 | 2015-01-08 | インスリン産生細胞の機能を保持する方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1915171B1 (enExample) |
| JP (2) | JP2009503093A (enExample) |
| CN (1) | CN101232899A (enExample) |
| AU (1) | AU2006275424B2 (enExample) |
| BR (1) | BRPI0614489A2 (enExample) |
| CA (1) | CA2617226A1 (enExample) |
| DK (1) | DK1915171T3 (enExample) |
| ES (1) | ES2439455T3 (enExample) |
| MX (1) | MX2008001643A (enExample) |
| WO (1) | WO2007016600A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015027543A (ja) * | 2009-03-04 | 2015-02-12 | マンカインド コーポレイション | 改善された乾燥粉末薬物送達システム |
| JP7778493B2 (ja) | 2015-06-04 | 2025-12-02 | キッコーマン株式会社 | フラビン結合型グルコースデヒドロゲナーゼを用いたグルコースの測定方法 |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| JP4681231B2 (ja) | 2002-03-20 | 2011-05-11 | マンカインド コーポレイション | 吸入装置 |
| ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
| HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
| MX373000B (es) | 2005-09-14 | 2020-05-21 | Mannkind Corp | Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas. |
| CN104383546B (zh) | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| MY155524A (en) | 2008-06-13 | 2015-10-30 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
| EP2609954B1 (en) | 2008-06-20 | 2021-12-29 | MannKind Corporation | An interactive apparatus for real-time profiling of inhalation efforts |
| TWI494123B (zh) | 2008-08-11 | 2015-08-01 | Mannkind Corp | 超快起作用胰島素之用途 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| SI2379100T1 (sl) * | 2009-01-08 | 2015-02-27 | Mannkind Corporation | Zdravljenje hiperglikemije z GLP-1 |
| US8538707B2 (en) | 2009-03-11 | 2013-09-17 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| AU2010259943C1 (en) | 2009-06-12 | 2016-03-03 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| JP5784622B2 (ja) | 2009-11-03 | 2015-09-24 | マンカインド コーポレ−ション | 吸入活動をシミュレートするための装置及び方法 |
| RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
| MX353285B (es) | 2011-04-01 | 2018-01-05 | Mannkind Corp | Paquete de blister para cartuchos farmaceuticos. |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| HK1201475A1 (en) | 2011-10-24 | 2015-09-04 | Mannkind Corporation | Methods and compositions for treating pain |
| AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
| US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
| BR112015023168B1 (pt) | 2013-03-15 | 2021-08-10 | Mannkind Corporation | Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina |
| BR122019026637B1 (pt) | 2013-07-18 | 2023-09-26 | Mannkind Corporation | Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco |
| CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| US9898585B2 (en) | 2014-01-31 | 2018-02-20 | Aseko, Inc. | Method and system for insulin management |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
| JP6989262B2 (ja) | 2014-10-27 | 2022-01-05 | アセコー インコーポレイテッド | 皮下外来患者管理 |
| EP3337402B1 (en) | 2015-08-20 | 2026-01-07 | Glytec, LLC | Diabetes management therapy advisor |
| CN110187123B (zh) * | 2019-05-06 | 2022-07-22 | 天津医科大学总医院 | 一种糖尿病早期诊断生物标志物及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002512607A (ja) * | 1997-04-02 | 2002-04-23 | パーデュー・リサーチ・ファウンデーション | タンパク質の経口デリバリー法 |
| WO2004012720A1 (en) * | 2002-07-26 | 2004-02-12 | Pfizer Limited | Process for making orally consumable dosage forms |
| WO2004080401A2 (en) * | 2003-03-06 | 2004-09-23 | Emisphere Technologies, Inc. | Oral insulin therapies and protocol |
| WO2005067964A1 (en) * | 2004-01-12 | 2005-07-28 | Mannkind Corporation | A method of reducing serum proinsulin levels in type 2 diabetics |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2395096T3 (es) * | 1999-06-29 | 2013-02-08 | Mannkind Corporation | Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas |
-
2006
- 2006-08-01 EP EP06789148.1A patent/EP1915171B1/en not_active Expired - Lifetime
- 2006-08-01 BR BRPI0614489-6A patent/BRPI0614489A2/pt not_active Application Discontinuation
- 2006-08-01 CA CA002617226A patent/CA2617226A1/en not_active Abandoned
- 2006-08-01 JP JP2008525132A patent/JP2009503093A/ja active Pending
- 2006-08-01 DK DK06789148.1T patent/DK1915171T3/da active
- 2006-08-01 MX MX2008001643A patent/MX2008001643A/es not_active Application Discontinuation
- 2006-08-01 CN CNA2006800283625A patent/CN101232899A/zh active Pending
- 2006-08-01 WO PCT/US2006/030014 patent/WO2007016600A2/en not_active Ceased
- 2006-08-01 AU AU2006275424A patent/AU2006275424B2/en not_active Ceased
- 2006-08-01 ES ES06789148.1T patent/ES2439455T3/es not_active Expired - Lifetime
-
2015
- 2015-01-08 JP JP2015002059A patent/JP2015091854A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002512607A (ja) * | 1997-04-02 | 2002-04-23 | パーデュー・リサーチ・ファウンデーション | タンパク質の経口デリバリー法 |
| WO2004012720A1 (en) * | 2002-07-26 | 2004-02-12 | Pfizer Limited | Process for making orally consumable dosage forms |
| WO2004080401A2 (en) * | 2003-03-06 | 2004-09-23 | Emisphere Technologies, Inc. | Oral insulin therapies and protocol |
| WO2005067964A1 (en) * | 2004-01-12 | 2005-07-28 | Mannkind Corporation | A method of reducing serum proinsulin levels in type 2 diabetics |
| JP2007517892A (ja) * | 2004-01-12 | 2007-07-05 | マンカインド コーポレイション | ２型糖尿病における血清プロインスリンレベルを低下させる方法 |
Non-Patent Citations (7)
| Title |
|---|
| CSNC200900243049; 医学のあゆみ Ｖｏｌ．１５６, 1991, ｐｐ．１０５５-８ * |
| JPN6010065295; Ｄｉａｂｅｔｅｓ Ｔｅｃｈｎｏｌ Ｔｈｅｒ Ｖｏｌ．４, 2002, ｐｐ．５８９-９４ * |
| JPN6010065296; Ｄｉａｂｅｔｏｌｏｇｉａ Ｖｏｌ．４４（Ｓｕｐｐｌ．１）, 2001, ｐ．Ａ２１２ * |
| JPN6011064829; Ｌａｎｃｅｔ Ｖｏｌ．３３３, 1989, ｐｐ．１２３５-６ * |
| JPN6011064830; Ｅｎｄｏｃｒｉｎｏｌ Ｍｅｔａｂ Ｃｌｉｎ Ｎｏｒｔｈ Ａｍ Ｖｏｌ．３３, 2004, ｐｐ．７５-９２ * |
| JPN6011064831; 医学のあゆみ Ｖｏｌ．１５６, 1991, ｐｐ．１０５５-８ * |
| JPN6011064832; Ａｍ Ｊ Ｍｅｄ Ｖｏｌ．１０８（６Ａ）, 2000, ｐｐ．１５Ｓ-２２Ｓ * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015027543A (ja) * | 2009-03-04 | 2015-02-12 | マンカインド コーポレイション | 改善された乾燥粉末薬物送達システム |
| JP7778493B2 (ja) | 2015-06-04 | 2025-12-02 | キッコーマン株式会社 | フラビン結合型グルコースデヒドロゲナーゼを用いたグルコースの測定方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1915171B1 (en) | 2013-11-20 |
| AU2006275424A1 (en) | 2007-02-08 |
| MX2008001643A (es) | 2008-04-07 |
| JP2015091854A (ja) | 2015-05-14 |
| WO2007016600A2 (en) | 2007-02-08 |
| ES2439455T3 (es) | 2014-01-23 |
| BRPI0614489A2 (pt) | 2011-03-29 |
| WO2007016600A3 (en) | 2007-05-31 |
| AU2006275424B2 (en) | 2013-01-10 |
| CA2617226A1 (en) | 2007-02-08 |
| CN101232899A (zh) | 2008-07-30 |
| DK1915171T3 (da) | 2013-12-09 |
| EP1915171A2 (en) | 2008-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015091854A (ja) | インスリン産生細胞の機能を保持する方法 | |
| US20070027063A1 (en) | Method of preserving the function of insulin-producing cells | |
| RU2688663C2 (ru) | Применение сверхбыстродействующего инсулина | |
| JP5719099B2 (ja) | 糖尿病治療における優れた血糖コントロール | |
| JP5918539B2 (ja) | Ｇｌｐ−１を用いる高血糖症の治療方法 | |
| CN101027082A (zh) | 降低2型糖尿病患者血清胰岛素原水平的方法 | |
| Rabiee et al. | Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy | |
| HUE025485T2 (en) | Respiratory dry powder formulation containing GLP-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration | |
| US20240342251A1 (en) | Method of treating hypoglycemia events in diabetes treatment | |
| HK1122213A (en) | Method of preserving the function of insulin-producing cells | |
| Khan et al. | DIABETES AND ITS TREATMENT BY GLUCAGON-LIKE PEPTIDE 1 ANALOGS AND DI-PEPTIDYL PEPTIDASE 4 INHIBITORS | |
| Codario | Non-Insulin Injectables | |
| HK1152257A (en) | Control of blood glucose in diabetes treatment using pulmonarily administered insulin in combination with basal insulin | |
| HK1161557A (en) | Control of blood glucose in diabetes treatment using pulmonarily administered insulin in combination with basal insulin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20090619 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090714 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090717 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090717 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120307 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120628 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20120712 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120724 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121029 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20121113 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20130111 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140314 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140409 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141007 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141010 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141107 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141112 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141208 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150108 |